A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Clinical trial NCT06092606 · UNKNOWN

Trial details

NCT number: NCT06092606
Sponsor: Monyan Pharmaceutical (Shanghai) Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer Heart Failure Arrhythmia Doxorubicin Induced Cardiomyopathy Doxorubicin Adverse Reaction

Start date: 2023-04-04
Primary completion: 2025-01-31
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.